Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 18, 2007

Cellartis and Partners Initiate an Almost $19M Stem Cell Development Collaboration

  • Cellartis and its partners, ITI Life Sciences and University of Glasgow, announced a GBP9.5-million, or $18.73-million, R&D program to develop human stem cells for pharmaceutical research. “This important collaboration is in line with our strategic goal of scaling up our human embryonic stem cell technology," points out Mats Lundwall, CEO of Cellartis.

    As part of this three-year program, Cellartis will set up an R&D and manufacturing facility at the Medipark in Dundee, Scotland. In addition to the ITI’s funding, Cellartis will receive a Regional Selective Assistance Award from the Scottish Executive for this establishment.

    While maintaining its Gothenburg headquarter, Cellartis says this expansion will enable it to take on emerging opportunities along with the Scottish stem cell community. "Life science research in Scotland, particularly in the stem cell area, is recognized internationally,” notes Lundwall. “And by establishing a research base in Scotland, we hope to contribute to the growth of this sector, while at the same time expanding our own business and operations in Scotland."



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »